LFA
BMRN icon

LGT Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

LGT Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$110 – 418
2025
Q2 		$110 Buy
+2
New +$118 ﹤0.01% 589
2024
Q4 		– Sell
-60
Closed -$4.22K – 723
2024
Q3 		$4.22K Hold
60
– – 0.01% 561
2024
Q2 		$4.94K Buy
+60
New +$5K 0.01% 596

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

LGT Financial Advisors's BMRN Position: Q3 2025 in Review

LGT Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 2 shares — an estimated $110 sold.

LGT Financial Advisors first reported a position in BMRN in Q2 2024 and held it in 3 quarters. The position peaked at $4.94K in Q2 2024. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • LGT Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 2 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $110.
  • LGT Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • LGT Financial Advisors's BioMarin Pharmaceuticals position peaked at $4.94K in Q2 2024.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on LGT Financial Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.